HDC Helminth Therapy
In a world where disease burdens are worsening, some parents have turned to alternative therapies with little to no help from the medical community. While we are not allowed to administer treatment protocols for HDC helminth therapy, Salisbury Pediatric Associates believes in open access to literature as it already exists. After speaking with Dr. William Parker, a helminth researcher at Duke University, we felt compelled to share his open access research of self reported treatment outcomes. The use of these therapies has been primarily focused on pediatric neurobehavioral disorders, allergic disease, autoimmune disease and inflammatory conditions. Based on current literature with self treating individuals, the success rate is quite high compared to a very low side effect risk. “Based on available data, Parker estimates that the chance of having a very favourable reaction to HDCs compared to a very negative reaction is about 25 to 1.”
